Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-01-24
2006-01-24
Shukla, Ram R. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S415000, C514S043000, C514S411000, C424S078380, C548S484000
Reexamination Certificate
active
06989362
ABSTRACT:
The present invention discloses that DARPP-32 is substrate for the cyclin dependent kinase Cdk5. The phosphorylation takes place at a specific threonine residue of DARPP-32 (Threonine 75). The Cdk5 catalyzed phosphorylation of DARPP-32 converts this protein into an inhibitor of the cAMP dependent protein kinase (PKA) and furthermore prevents it from being converted to an inhibitor of protein phosphatase 1 (PP1). Methods of identifying agents that modulate the phosphorylation of DARPP-32 by Cdk5 are disclosed. Methods of treating dopamine dysfunction in animal subjects are also provided.
REFERENCES:
patent: 5777195 (1998-07-01), Fienberg et al.
patent: 6013621 (2000-01-01), Nishi et al.
patent: WO 99/20273 (1999-04-01), None
Greengard The neurobiolgy of slow synaptic transmission vol. 294 Nov. 2, 2001.
Jaber et al. Dopamine receptors and brain function pp. 1503-1519 Jun. 12, 1996.
Ahuja et al., 1997, Developmental Genetics, 21:258-67.
Altucci et al., 1997, Endocrinology, 138:978-984.
Ando et al., 1997, J. Biochem, 122:409-414.
Backstrom et al., 1998, Society for Neuroscience, 24:284 Article No. 116.3.
Besset et al., 1998, Molecular Reproduction and Development, 50:18-29.
Cai et al., 1997, Neurosci Res, 28:355-60.
Chang et al., 1999, Chemistry & Biology, 6:361-75.
Chin et al., 1999, The Journal of Biological Chemistry, 274:7120-7127.
Chou et al., 1999, Biochemical and Biophysical Research Communications, 259:420-28.
Delalle t al., 1997, Journal of Neurocytology, 26:283-296.
Fienberg et al., 1998, Science, 281:838-842.
Filgueira d Azevedo, Jr. et al., 1996, Biochemistry, 93:2735-2740.
Fletcher et al., 1999, The Journal of Biological Chemistry, 274:4027-4035.
Gervasi and Szaro, 1995, Molecular Brain Research, 33: 192-200.
Girault et al., 1989, The Journal of Biological Chemistry, 264:21748-21759.
Gray et al., 1998, Current Opinion in Neurobiology, 8:330-334.
Green et al., 1997, Neurochem., 31:617-623.
Guidato et al., 1998, J. Neurochem., 70:335-340.
Hasegawa et al., 1996, Neurochem., 28:221-229.
Hellmich et al., 1992, Neurobiology, 89:10867-10871.
Hemmings, Jr. et al., 1989, The Journal of Biological Chemistry, 264:7726-7733.
Hemmings, Jr. et al., 1984, Nature, 310:7726-7733.
Henchcliffe and Burke, 1997, Neuroscience Letter, 230:41-44.
Hisanaga et al., 1993, The Journal of Biological Chemistry, 268:15056-15060.
Horiuchi et al., 1990, The Journal of Biological Chemistry, 265:9476-9484.
Hosoi et al., 1995, J. Biochem, 117:741-749.
Ino and Chiba, 1996, Brain Research, 732:170-185.
Iseki et al., 1997, Surgery, 122:187-195.
Ishiguro et al., 1994, FEBS Letters, 342:203-208.
Ishiguro et al., 1995, Neuroscience Letters, 202:81-84.
Ishizuka et al., 1995, Gene, 166:267-271.
Klauck et al., 1996, Science, 271:1589-1592.
Kobayashi et al., 1993, FEBS, 335:171-175.
Lazaro et al., 1996, Neuroscience Letters, 218:21-24.
Lazzaro et al., 1997, Journal of Neurochemistry, 69:348.
Lew et al., 1994, Nature, 371:423-426.
Liu et al., 1995, American Journal of Pathology, 146:228-238.
Meijer et al., 1997, Eur. J. Biochem., 243:527-536.
Miyajima et al., 1995, NeuroReport 6:1130-1132.
Moorthamer et al., 1999, FEBS Letters, 446:343-350.
Nakamura et al., 1997, Neurology, 48:267-270.
Nakamura et al., 1997, Acta Neuropathol, 94:153-157.
Ohshima et al., 1995, Genomics, 28:585-588.
Ohshima et al., 1996, Proc. Natl, Acad. Sci., 93:11173-11178.
Ouimet et al., 1998, Brain Research, 808:8-12.
Pant et al., 1997, Brain Research, 765:259-266.
Pant and Veeranna, 1995, Biochem. Cell Biol., 73:575-592.
Park et al., 1997, The Journal of Neuroscience, 17:8975-8983.
Pato et al., 1996, The Journal of Biological Chemistry, 271:2689-2695.
Pawson and Scott, 1997, Science, 278:2075-2080.
Philpott et al., 1999, Developmental Biology 207:119-132.
Pigino et al., 1997, Journal of Cell Science, 110:257-270.
Roche et al., 1996, Neuron, 16:1179-1188.
Saito et al., 1998, Biochemical and Biophysical Research Communications, 252:775-778.
Sauer et al., 1996, Molecular Biology of the Cell, 7:1759-1769.
Sharma et al., 1999, J. Neurochem., 73:79-86.
Sharma et al., 1999, The Journal of Biological Chemistry, 274:9600-9606.
Sharma et al., 1998, Biochemistry, 37:4759-4766.
Shuang et al., 1998, The Journal of Biological Chemistry, 273:4957-4966.
Snyder et al., 1992, The Journal of Neuroscience, 12:3071-3083.
Songyang et al., 1996, Molecular and Cellular Biology, 16:6486-6493.
Sun et al., 1996, The Journal of Biological Chemistry, 271:14245-14251.
Surmeier et al., 1995, Neuron, 14:385-397.
Takahashi et al., 1995, The Journal of Neuroscience, 15:6222-6229.
Tsai et al., 1993, Development, 119:1029-1040.
Tsai et al., 1994, Nature, 371:419-423.
Tsai et al., 1998, Society for Neuroscience, 24:284 Article No. 116.4.
Veeranna et al., 1997, Dev Neurosci, 19:172-183.
Veeranna et al., 1996, Neurochemical Research, 21:629-636.
Veeranna et al., 1995, J. Neurochem., 64:2681-2690.
Westphal et al., 1999, The Journal of Biological Chemistry, 274:687-692.
Xiong et al., 1997, Molecular and Cellular Biology, 17:6585-6597.
Yamaguchi et al., 1996, Acta Neuropathol, 92:232-241.
Zhang et al., 1997, Developmental Biology 183:222-233.
Bibb et al., 1999,Nature,402:669-71.
Greengard et al., (Jul.) 1999, Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade, Neuron 23: 435-47.
Hiroi et al., 1999, Neuronal and behavioral abnormalities in striatal function in DARPP-32 mutant mice, European Journal of Neuroscience 11:1114-18.
Masserano et al., 1994, Effects of chronic cocaine administration on3H-dopamine uptake in the nucleus accumbens, striatum and frontal cortex of rats, J. Pharmacol. Exp Ther. 270: 133-41.
Self et al., 1996, Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists, Science 271 (5255):1586-89.
Shimosato et al., 1995, Increased polyamine levels and changes in the sensitivity to convulsions during chronic treatment with cocaine in mice, Brain Research 684: 243-47.
Koob and Nestler, 1997, The neurobiology of drug addiction, J. Neuropsychiatry Clin. Neurosci. 9(3):482-97.
Bibb James A.
Greengard Paul
Day Jones
Shukla Ram R.
The Rockefeller University
LandOfFree
Methods of treating dopamine dysregulation using agents that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating dopamine dysregulation using agents that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating dopamine dysregulation using agents that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536014